Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 66 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $115,676 | -67.9% | 23,704 | -5.1% | 0.00% | – |
| Q3 2022 | $360,000 | +13.6% | 24,977 | +19.4% | 0.00% | – |
| Q2 2022 | $317,000 | +39.0% | 20,924 | +8.6% | 0.00% | – |
| Q1 2022 | $228,000 | -22.4% | 19,265 | +6.6% | 0.00% | – |
| Q4 2021 | $294,000 | -39.1% | 18,066 | +6.6% | 0.00% | – |
| Q3 2021 | $483,000 | -8.3% | 16,942 | +8.8% | 0.00% | – |
| Q2 2021 | $527,000 | +18.4% | 15,567 | +5.8% | 0.00% | – |
| Q1 2021 | $445,000 | -67.8% | 14,716 | -47.3% | 0.00% | -100.0% |
| Q4 2020 | $1,383,000 | +22.2% | 27,939 | -5.2% | 0.00% | 0.0% |
| Q3 2020 | $1,132,000 | -29.5% | 29,476 | -20.7% | 0.00% | 0.0% |
| Q2 2020 | $1,605,000 | +190.2% | 37,156 | +75.5% | 0.00% | – |
| Q1 2020 | $553,000 | -43.3% | 21,174 | -32.2% | 0.00% | -100.0% |
| Q4 2019 | $976,000 | +296.7% | 31,245 | +231.9% | 0.00% | – |
| Q3 2019 | $246,000 | – | 9,415 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sofinnova Investments, Inc. | 2,194,278 | $84,238,000 | 6.25% |
| Burrage Capital Management LLC | 123,025 | $4,723,000 | 3.73% |
| MPM BioImpact LLC | 337,291 | $12,949,000 | 3.12% |
| First Light Asset Management, LLC | 608,193 | $23,349,000 | 2.39% |
| Cormorant Asset Management, LP | 1,397,700 | $53,658,000 | 2.06% |
| SPHERA FUNDS MANAGEMENT LTD. | 396,521 | $15,222,000 | 1.50% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 801 | $33,000 | 0.61% |
| Artal Group S.A. | 285,028 | $10,942,000 | 0.27% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 298,213 | $11,448,000 | 0.24% |
| Virtus ETF Advisers LLC | 7,309 | $281,000 | 0.15% |